Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving

Journal of Immunology

Volumn 181, Issue 4, 2008, Pages 2916-2924

  Beum, Paul V ^a   Lindorfer, Margaret A ^a   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; FC GAMMA RECEPTOR I; FC RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; OPSONIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL KILLING; CELL LOSS; CONTROLLED STUDY; DAUDI CELL; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MONOCYTE; NATURAL KILLER CELL; OPSONIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SHAVING; CELL COMMUNICATION; CELL CULTURE; CELL DEATH; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; B-LYMPHOCYTES; CELL COMMUNICATION; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MONOCYTES; OPSONIN PROTEINS;

EID: 53149151480     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.4.2916     Document Type: Article

References (76)

1. Nadler, L. M., P. Stashenko, R. Hardy, W. D. Kaplan, L. N. Button, D. W. Kufe, K. H. Antman, and S. F. Schlossman. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res. 40: 3147-3154.
2. Ritz, J., J. M. Pesando, S. E. Sallan, L. A. Clavell, J. Notis-McConarty, P. Rosenthal, and S. F. Scholossman. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141-152.
3. Bertram, J. H., P. S. Gill, A. M. Levine, D. Boquiren, F. M. Hoffman, P. Meyer, and M. S. Mitchell. 1986. Monoclonal antibody T101 in T cell malignancies: A clinical, pharmacokinetic, and immunologic correlation. Blood 68: 752-761.
4. Carter, P. 2001. Improving the efficacy of antibody-based cancer therapies. Nature 1: 118-129.
5. Glennie, M. J., and J. G. J. van de Winkel. 2003. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8: 503-509.
6. Stern, M., and R. Herrmann. 2005. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54: 11-29.
7. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
8. Scallon, B. J., L. A. Snyder, G. M. Anderson, Q. Chen, L. Yan, L. M. Weiner, and M. T. Nakada. 2006. A review of antibody therapeutics and antibody-related technologies for oncology. J. Immunother. 29: 351-364.
9. Desoize, B. 2007. Antibodies in cancer treatment. Crit. Rev. Oncol. Hematol. 62: 23-25.
10. Maloney, D. G., A. J. Grillo-López, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
11. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
12. Maloney, D. G. 1999. Preclinical and phase I and II trials of Rituximab. Semin. Oncol. 26: 74-78.
13. McLaughlin, P. 2001. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit. Rev. Oncol. Hematol. 40: 3-16.
14. Johnson, P., and M. Glennie. 2003. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30: 3-8.
15. Silverman, G. J., and S. Weisman. 2003. Rituximab therapy and autoimmune disorders. Prospects for anti-B Cell therapy. Arthritis Rheum. 48: 1484-1492.
16. Edwards, J. C. W., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6: 394-403.
17. Cohen, S. B., P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, et al. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safty at twenty-four weeks. Arthritis Rheum. 54: 2793-2806.
18. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
19. Harjunpää, A., S. Junnikkala, and S. Meri. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51: 634-641.
20. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazari, G. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95: 3900-3908.
21. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
22. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
23. Manches, O., G. Lui, L. Chaperot, R. Gressin, J. P. Molens, M. C. Jacob, J. J. Sotto, D. Leroux, J. C. Bensa, and J. Plumas. 2002. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 101: 949-954.
24. Cragg, M. S., S. M. Morgan, H. T. C. Chan, B. P. Morgan, A. V. Filatov, P. W. M. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid "rafts." Blood 101: 1045-1052.
25. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of Rituximab in vivo. J. Immunol. 171: 1581-1587.
26. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to Rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
27. Golay, J., M. Manganini, V. Facchinetti, R. Gramigna, R. Broady, G. Borleri, A. Rambaldi, and M. Introna. 2003. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88: 1002-1012.
28. + cells by Rituximab. Blood 101: 1071-1079.
29. Gaetno, N. D., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171: 1581-1587.
30. Dall'Ozzo, S., S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault. 2004. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64: 4664-4669.
31. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
32. Bowles, J. A., and G. J. Weiner. 2005. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 304: 88-99.
33. Lefebvre, M.-L., S. W. Krause, M. Salcedo, and A. Nardin. 2006. Ex vivoactivated human macrophages kill chronic lymphocytic leukemia cells in the presence of Rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29: 388-397.
34. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
35. Tedder, T. F., A. Baras, and Y. Xiu. 2006. Fcγreceptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28: 351-364.
36. Glennie, M. J., R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
37. Anolik, J. H., D. Campbell, R. E. Felgar, F. Young, I. Sanz, J. Rosenblatt, and R. J. Looney. 2003. The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48: 455-459.
38. Gluck, W. L., D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al. 2004. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10: 2253-2264.
39. Fischer, L., O. Penack, C. Gentilini, A. Nogai, A. Muessig, E. Thiel, and L. Uharek. 2006. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp. Hematol. 34: 753-759.
40. Preithner, S., S. Elm, S. Lippold, M. Locher, A. Wolf, A. J. da Silva, P. A. Baeuerle, and N. S. Prang. 2006. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43: 1183-1193.
41. Bowles, J. A., S.-Y. Wang, B. K. Link, G. Beuerlein, M.-A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, J. B. Breitmeyer, and G. J. Weiner. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654.
42. Hatjiharissi, E., L. Xu, D. D. Santos, Z. R. Hunter, B. T. Ciccarelli, S. Verselis, M. Modica, Y. Cao, R. J. Manning, X. Leleu, et al. 2007. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 110: 2561-2564.
43. Griffin, F. M., J. A. Griffin, and S. C. Silverstein. 1976. Studies on the mechanism of phagocytosis: II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J. Exp. Med. 144: 788-809.
44. Williams, M. E., J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor. 2006. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177: 7435-7443.
45. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
46. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
47. Craig, M. L., A. J. Bankovich, and R. P. Taylor. 2002. Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophages. Clin. Immunol. 105: 36-47.
48. Gyimesi, E., A. J. Bankovich, T. A. Schuman, J. B. Goldberg, M. A. Lindorfer, and R. P. Taylor. 2004. Staphylococcus aureus bound to complement receptor 1 on human erythocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol. Let. 95: 185-192.
49. Barnes, C. R., G. L. Mandell, H. T. Carper, S. Luong, and G. W. Sullivan. 1995. Adenosine modulation of tumor necrosis factor-α-induced neutrophil activation. Biochem. Pharmacol. 50: 1851-1857.
50. Bhat, R., and C. Watzl. 2007. Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies. PLoS ONE 2: 1-7.
51. Wallace, P. K., P. Kaufman, L. Lewis, T. Keler, A. Givan, J. Fisher, M. Waugh, A. Wahner, P. Guyre, M. Fanger, and M. Ernstoff. 2001. Bispecific antibodytargeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J. Immunol. Methods 248: 167-182.
52. Stockmeyer, B., D. Elsasser, M. Dechant, R. Repp, M. Gramatzki, M. Glennie, J. G. van de Winkle, and T. Valerius. 2001. Mechanisms of G-CSF- or GMCSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J. Immunol. Methods 248: 103-111.
53. Stockmeyer, B., M. Schiller, R. Repp, H. M. Lorenz, J. R. Kalden, M. Gramatzki, and T. Valerius. 2002. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10-a humanized human leucocyte antigen DR antibody. Br. J. Haematol. 118: 959-967.
54. Whale, T. A., T. K. Beskorwayne, L. A. Babiuk, and P. J. Griebel. 2006. Bovine polymorphonuclear cells passively acquire membrane lipids and integral membrane proteins from apoptotic cells and necrotic cells. J. Leukocyte Biol. 79: 1226-1233.
55. Griffin, F. M., J. A. Griffin, J. E. Leider, and S. C. Silverstein. 1975. Studies on the mechanism of phagocytosis: I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J. Exp. Med. 142: 1263-1282.
56. Janssen, E., K. Tabeta, M. J. Barnes, S. Rutschmann, S. McBride, K. S. Bahjat, S. P. Schoenberger, A. N. Theofilopoulos, B. Beutler, and K. Hoebe. 2006. Ef-ficient T cell activation via a Toll-interleukin 1 receptor-independent pathway. Immunity 24: 787-799.
57. Tabiasco, J., A. Vercellone, F. Meggetto, D. Hudrisier, P. Brousset, and J. J. Fournie. 2003. Acquisition of viral receptor by NK cells through immunological synapse. J. Immunol. 170: 5993-5998.
58. Tabiasco, J., E. Espinosa, D. Hudrisier, E. Joly, J. J. Fournie, and A. Vercellone. 2002. Active trans-synaptic capture of membrane fragments by natural killer cells. Eur. J. Immunol. 32: 1502-1508.
59. Joly, E., and D. Hudrisier. 2003. What is trogocytosis and what is its purpose? Nat. Immunol. 4: 815.
60. Hudrisier, D., A. Aucher, A. L. Puaux, C. Bordier, and E. Joly. 2007. Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J. Immunol. 178: 3637-3647.
61. Taylor, R. P., and M. A. Lindorfer. 2007. Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol. 3: 86-95.
62. Wang, S. Y., E. Racila, R. P. Taylor, and G. J. Weiner. 2008. NK cell activation and antibody dependent cellular cytotoxicity induced by Rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111: 1456-1463.
63. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes: in vivo effects of IgG and IgM complement fixing sites. J. Clin. Invest. 51: 575-582.
64. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
65. Song, S., A. R. Crow, V. Siragam, J. Freedman, and A. H. Lazarus. 2005. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105: 1546-1548.
66. Kavai, M., and G. Szegedi. 2007. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun. Rev. 6: 497-502.
67. Harrison, P. T., W. Davis, J. C. Norman, A. R. Hockaday, and J. M. Allen. 1994. Binding of monomeric immunoglobulin G triggers FcγRI-mediated endocytosis. J. Biol. Chem. 269: 24396-24402.
68. Davis, W., P. T. Harrison, M. J. Hutchinson, and J. M. Allen. 1995. Two distinct regions of FcγRI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J. 14: 432-441.
69. Lovdal, T., E. Andersen, and A. B. T. Brech. 2000. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J. Cell Sci. 113: 3255-3266.
70. Guyre, C., T. Keler, S. Swink, L. Vitale, R. Graziano, and M. Fanger. 2001. Receptor modulation by FcγRI-specific fusion proteins is dependent on receptor number and modified by IgG. J. Immunol. 167: 6303-6311.
71. Li, Y., M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2007. Rituximab/CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J. Immunol. 179: 4263-4271.
72. Lopes de Menezes, D. E., K. Denis-Mize, Y. Tang, H. Ye, J. C. Kunich, E. N. Garrett, J. Peng, L. S. Cousens, A. B. Gelb, C. Heise, et al. 2007. Recombinant interleukin-2 signficantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J. Immunother. 30: 64-74.
73. + donor lymphocytes in children. Bone Marrow Transplant. 29: 497-502.
74. Clemenceau, B., G. Gallot, R. Vivien, J. Gaschet, M. Campone, and H. Vie. 2006. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J. Immunother. 29: 53-60.
75. Barfield, R. C., M. Otto, J. Houston, M. Holladay, T. Geiger, J. Martin, T. Leimig, P. Gordon, X. Chen, and R. Handgretinger. 2004. A one-step largescale method for T- and B-cell depeltion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6: 1-6.
76. Klingemann, H. G. 2005. Natural killer cell-based immunotherapetic strategies. Cytotherapy 7: 16-22.